H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...

Scotiabank initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 price target Maximize Your Portfolio with Data ...

VKTX stock opened at $30.48 on Thursday. Viking Therapeutics has a fifty-two week low of $28.64 and a fifty-two week high of $99.41. The business’s 50-day moving average is $37.97 and its two ...

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street's major indices kicked off the trading on a positive note ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) gapped down before the market opened on Thursday following a dissappointing earnings announcement. The stock had previously closed at $ ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

At recent prices, Viking Therapeutics has a $3.7 billion market cap. This is a low valuation for a company that could have a blockbuster obesity treatment, and a MASH treatment ready to launch in ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have ...